Cumulative all-cause mortality following BAV in series reported prior to and after the introduction of TAVI in 2002
| Era | Author | Subgroup | Year | Study design | Patients | Hospital* | 30-day | 6-month | 1-year | 5-year |
|---|---|---|---|---|---|---|---|---|---|---|
| No TAVI (pre-2002) | Lababidi et al29 | NA | 1984 | SC, P | 23 | NA | NA | NA | NA | NA |
| Walls et al30 | NA | 1984 | SC, P | 27 | 4% | NA | NA | NA | NA | |
| Block and Palacios31 | NA | 1987 | SC | 35 | 6% | NA | NA | NA | NA | |
| Dorros et al32 | NA | 1987 | SC | 10 | NA | NA | NA | NA | NA | |
| Schneider et al33 | NA | 1987 | SC | 6 | 0% | NA | NA | NA | NA | |
| Isner et al34 | NA | 1987 | SC | 9 | NA | NA | NA | NA | NA | |
| McKay et al35 | NA | 1987 | SC | 32 | 10% | NA | NA | NA | NA | |
| Cribier et al36 | NA | 1987 | SC | 92 | 3% | NA | NA | NA | NA | |
| Letac et al37 | NA | 1988 | SC | 218 | 5% | NA | NA | NA | NA | |
| Nishimura et al38 | NA | 1988 | SC, P | 25 | 1% | 16% | 48% | NA | NA | |
| Litvack et al39 | NA | 1988 | SC | 25 | 1% | NA | NA | NA | NA | |
| Safian et al40 | NA | 1988 | SC | 170 | 4% | NA | 18% | 26% | NA | |
| NHLBI Registry18 | NA | 1991 | MC, R | 674 | 3% | 14% | NA | 36% | NA | |
| Mansfield Registry19 45 | NA | 1991 | MC, P | 492 | 5% | NA | 23% | 36% | NA | |
| Lieberman et al41 | NA | 1995 | SC | 165 | NA | NA | NA | 40% | NA | |
| TAVI (2002 to current) | Agarwal et al42 | NA | 2005 | SC, R | 212 | 8% | 10% | NA | 36% | 86% |
| Klein et al43 | NA | 2006 | SC, R | 78 | 1% | NA | NA | 62% | 86% | |
| Tissot et al21 | BAV alone | 2011 | SC, P | 41 | NA | NA | NA | 67% | NA | |
| BAV bridge | 140 | NA | NA | NA | 6% | NA | ||||
| Khawaja et al12 | NA | 2013 | MC | 423 | 2.4% | 14% | NA | 36% | NA | |
| Ben-Dor et al22 | NA | 2013 | SC, P | 472 | 2.5% | NA | NA | NA | NA | |
| Saia et al10 | B-TAVI | 2013 | SC, R | 162 | NA | NA | NA | 21% | NA | |
| B-AVR | 197 | NA | NA | NA | 22% | NA | ||||
| Shock | 23 | NA | NA | NA | 71% | NA | ||||
| Pall. | 133 | NA | NA | NA | 44% | NA | ||||
| Eltchaninoff et al44 | BAV | 2014 | SC, R | 238 | NA | NA | NA | 54% | 99% | |
| B-TAVI | 54 | NA | NA | NA | 26% | 91% | ||||
| B-AVR | 31 | NA | NA | NA | 23% | 81% | ||||
| Moretti et al23 | Dest. | 2015 | MC, R | 416 | NA | 6.5% | NA | NA | NA | |
| B-TAVI | 320 | NA | 6.2% | NA | NA | NA | ||||
| B-AVR | 75 | NA | 7.4% | NA | NA | NA |
*Hospital: mortality rate during procedure, after 24 hours and at time of discharge combined.
BAV, balloon aortic valvuloplasty; B-AVR, bridge to AVR; B-TAVI, bridge to TAVI; Dest., destination therapy; MC, multicentre; NHLBI, National Heart Lung and Blood Institute; P, prospective; Pall., palliation; R, retrospective; SC, single-centre; TAVI, transcatheter aortic valve implantation.